CT101

About Cura Therapeutics

Cura Therapeutics is a private, preclinical-stage biotech founded in 2018 and based in San Diego, California. The company's core innovation is a multimodal immunotherapy platform that generates single recombinant proteins capable of engaging multiple disease pathways concurrently, with an initial focus on solid tumors. Its lead program, CT101, is positioned as a first-in-class biologic targeting immunostimulation, anti-metastasis, and anti-angiogenesis. Cura is actively seeking partnerships to advance its pipeline.

Therapeutic Areas